Wefunder logo

Invest in Ventoux Biosciences

Transforming Dupuytren's Disease Treatment Novel Non-Surgical Disease Slowing Treatments

Exclusive
Friends Invest First
Public Launch on May 9 @ 8:00 PM ET
--
day
--
hour
--
min
--
sec
INVESTMENT TERMS
Future Equity
$12M valuation cap

Highlights

1
Dupuytren's impacts >40m patients in US and Europe and global disease market size est. at USD $4.3B
2
No cure and no approved pharmacologic disease modifying options, surgery is mainstay of treatment
3
High patient dissatisfaction with limited treatment options, strong interest in novel options
4
VEN-201, our lead asset, represents a potential paradigm shift in treatment

Our Team

Transforming the $4B Dupuytren's Disease Market with Novel Non-Surgical Treatments



























Downloads

Overview